|
|
||||||||
J Thorac Cardiovasc Surg 2004;127:302-303
© 2004 The American Association for Thoracic Surgery
Letter to the editor |
Department of Cardiothoracic Surgery, University of Aachen, Aachen, Germany
To the Editor:
I read the article of Casarotto and colleagues1 with great interest. The article described a patient with Castleman disease who was treated with chemotherapy, leading to a dilated cardiomyopathy. Because of the neoplasm, cardiac transplantation was contraindicated. Because of a progredient severe heart failure, the patient had to be supported with a Novacor (World Heart Corporation, Ottawa, Ontario, Canada) left ventricular assist device (LVAD). After a total of 1512 days, the patient had no signs of a relapse of Castleman disease and underwent orthotopic heart transplantation.
The number of patients with severe heart failure after chemotherapy for neoplasms should not be underestimated: from 1990 to 1996, cardiac transplantation was performed in 89 selected patients in the United States for this indication.2 The number of patients in whom cardiac transplantation cannot be performed because there is no proof of cure of the neoplasm is probably much higher. Therefore these patients are not so rare as might be supposed, and alternative treatment concepts are necessary.
Recently, I introduced a canine model for research on partial left ventriculectomy (PLV).3,4 Heart failure was induced by intracoronary doxorubicin administration, leading to a dilated cardiomyopathy with histologic myocardial changes similar to those described by Casarotto and colleagues.1 PLV was performed by resecting the interpapillary segment of the left ventricle (group 2). Measurement of hemodynamic and echocardiographic parameters demonstrated an improvement of left ventricular function relative to a control group without PLV (group 1; Table 1).
|
I congratulate Casarotto and colleagues1 on their successful management of this difficult case. However, I encourage cardiac surgeons to take alternative treatment options such as PLV into consideration in such challenging cases.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Christiansen and R. Autschbach Doxorubicin in experimental and clinical heart failure Eur J Cardiothorac Surg, October 1, 2006; 30(4): 611 - 616. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |